Found: 32
Select item for more details and to access through your institution.
Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices.
- Published in:
- Clinical Pharmacology in Drug Development, 2019, v. 8, n. 1, p. 40, doi. 10.1002/cpdd.454
- By:
- Publication type:
- Article
Ertugliflozin Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients With Type 2 Diabetes: Analyses From VERTIS CV.
- Published in:
- Journal of Clinical Endocrinology & Metabolism, 2023, v. 108, n. 8, p. 2042, doi. 10.1210/clinem/dgac764
- By:
- Publication type:
- Article
Ertugliflozin, renoprotection and potential confounding by muscle wasting. Reply to Groothof D, Post A, Gans ROB et al [letter].
- Published in:
- 2022
- By:
- Publication type:
- Letter
Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial.
- Published in:
- Diabetologia, 2021, v. 64, n. 6, p. 1256, doi. 10.1007/s00125-021-05407-5
- By:
- Publication type:
- Article
Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials.
- Published in:
- Diabetologia, 2020, v. 63, n. 6, p. 1128, doi. 10.1007/s00125-020-05133-4
- By:
- Publication type:
- Article
Hypoglycaemia and kidney events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: Observations from the VERTIS CV trial.
- Published in:
- Diabetes, Obesity & Metabolism, 2024, v. 26, n. 8, p. 3478, doi. 10.1111/dom.15687
- By:
- Publication type:
- Article
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 5, p. 1398, doi. 10.1111/dom.14965
- By:
- Publication type:
- Article
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV, a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
- Published in:
- Diabetes, Obesity & Metabolism, 2023, v. 25, n. 3, p. 758, doi. 10.1111/dom.14923
- By:
- Publication type:
- Article
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1829, doi. 10.1111/dom.14769
- By:
- Publication type:
- Article
Cardiorenal outcomes with ertugliflozin assessed according to baseline glucose‐lowering agent: An analysis from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 7, p. 1245, doi. 10.1111/dom.14691
- By:
- Publication type:
- Article
The differential effects of ertugliflozin on glucosuria and natriuresis biomarkers: Prespecified analyses from VERTIS CV.
- Published in:
- Diabetes, Obesity & Metabolism, 2022, v. 24, n. 6, p. 1114, doi. 10.1111/dom.14677
- By:
- Publication type:
- Article
The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naïve patients with type 2 diabetes mellitus: a randomized controlled trial.
- Published in:
- Diabetology & Metabolic Syndrome, 2012, v. 4, n. 1, p. 36, doi. 10.1186/1758-5996-4-36
- By:
- Publication type:
- Article
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.
- Published in:
- European Heart Journal, 2023, v. 44, n. 48, p. 5163, doi. 10.1093/eurheartj/ehad639
- By:
- Publication type:
- Article
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial.
- Published in:
- Sleep & Breathing, 2023, v. 27, n. 2, p. 669, doi. 10.1007/s11325-022-02594-2
- By:
- Publication type:
- Article
Assessment of the cardiovascular safety of saxagliptin in patients with type 2 diabetes mellitus: pooled analysis of 20 clinical trials.
- Published in:
- Cardiovascular Diabetology, 2014, v. 13, n. 1, p. 2, doi. 10.1186/1475-2840-13-33
- By:
- Publication type:
- Article
Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus.
- Published in:
- Diabetes & Vascular Disease Research, 2011, v. 8, n. 2, p. 125, doi. 10.1177/1479164111404575
- By:
- Publication type:
- Article
Kidney outcomes using a sustained ≥40% decline in eGFR: A meta‐analysis of SGLT2 inhibitor trials.
- Published in:
- Clinical Cardiology, 2021, v. 44, n. 8, p. 1139, doi. 10.1002/clc.23665
- By:
- Publication type:
- Article
Severe leptin resistance in brown fat-deficient uncoupling protein promoter-driven diphtheria toxin A mice despite suppression of hypothalamic neuropeptide Y and circulating corticosterone concentrations.
- Published in:
- 1998
- By:
- Publication type:
- journal article
Activation of β<sub>3</sub> Adrenergic Receptors Suppresses Leptin Expression and Mediates a Leptin-Independent Inhibition of Food Intake in Mice.
- Published in:
- Diabetes, 1996, v. 45, n. 7, p. 909, doi. 10.2337/diab.45.7.909
- By:
- Publication type:
- Article
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.
- Published in:
- Diabetes Therapy, 2023, v. 14, n. 2, p. 319, doi. 10.1007/s13300-022-01345-6
- By:
- Publication type:
- Article
Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV.
- Published in:
- Diabetes Therapy, 2021, v. 12, n. 5, p. 1279, doi. 10.1007/s13300-021-01033-x
- By:
- Publication type:
- Article
Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.
- Published in:
- Diabetes Therapy, 2020, v. 11, n. 6, p. 1347, doi. 10.1007/s13300-020-00803-3
- By:
- Publication type:
- Article
Initial eGFR Changes with Ertugliflozin and Associations with Clinical Parameters: Analyses from the VERTIS CV Trial.
- Published in:
- American Journal of Nephrology, 2022, v. 53, n. 7, p. 516, doi. 10.1159/000524889
- By:
- Publication type:
- Article
A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy.
- Published in:
- BMC Endocrine Disorders, 2014, v. 14, n. 1, p. 1, doi. 10.1186/1472-6823-14-17
- By:
- Publication type:
- Article
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial.
- Published in:
- Diabetes Care, 2015, v. 38, n. 6, p. 1145, doi. 10.2337/dc14-2868
- By:
- Publication type:
- Article
Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial.
- Published in:
- Diabetes Care, 2015, v. 38, n. 4, p. 696, doi. 10.2337/dc14-1850
- By:
- Publication type:
- Article
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ⩾ 65 years) with inadequately controlled type 2 diabetes mellitus.
- Published in:
- Clinical Interventions in Aging, 2013, v. 8, p. 419, doi. 10.2147/CIA.S41246
- By:
- Publication type:
- Article
796-P: Cardiorenal Outcomes with Ertugliflozin by Baseline Cardiorenal Medications: An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-796-P
- By:
- Publication type:
- Article
786-P: Glycemic Efficacy and Safety of Ertugliflozin (ERTU) in Patients with Type 2 Diabetes (T2D) and Chronic Kidney Disease Stage 3 (CKD 3): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-786-P
- By:
- Publication type:
- Article
785-P: Ertugliflozin (ERTU) Delays Insulin Initiation and Reduces Insulin Dose Requirements in Patients with Type 2 Diabetes (T2D): An Analysis From VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-785-P
- By:
- Publication type:
- Article
783-P: Cardiorenal Outcomes with Ertugliflozin by Baseline (BL) Glucose-Lowering Agent (GLA): An Analysis from VERTIS CV.
- Published in:
- Diabetes, 2021, v. 70, p. N.PAG, doi. 10.2337/db21-783-P
- By:
- Publication type:
- Article
1197-P: Two-Year Effects of Ertugliflozin on Renal Function.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1197-P
- By:
- Publication type:
- Article